Revolution Medicines
- Market cap
- 43.05B
- P/E (TTM)i
- -22.65
- P/Bi
- 16.52
- EPSi
- -5.95
- Div yieldi
- 0.00%
- 52W posi
- 87%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Revolution Medicines closed at 200.87, up 0.50%. Its market capitalisation is about 43.05B, the #499 most valuable US-listed company we track. Wall Street's 22-analyst consensus lands on Buy, with a price target averaging 261.75 (+30% from here). Over the past year the stock has ranged from 47.45 to 224.31; it now sits 87% up that band.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 1% of the universe, above its 200-day average.
- Signal has read BUY for 1 month.
- Its last 5 Buy calls have averaged +12% over the following quarter.
- Recent price momentum is +168.4% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 4.5% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -4,207.1% | Better than 0% |
| Net margin | -3,768.3% | Better than 0% |
| Return on equity | -58.1% | Better than 3% |
| Return on invested capital | -57.2% | Better than 1% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 9.0% | Better than 74% |
| 6-month return | 115.7% | Better than 97% |
| 12-month return (ex latest month) | 350.9% | Better than 99% |
| Distance below 52-week high | 7.4% | Better than 85% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.1x | Better than 95% |
| Debt to assets | 6.7% | Better than 82% |
| Interest coverage | -45.7x | Better than 3% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 26.0% | Better than 52% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 199.87
- Open
- 198.18
- Day range
- 196.25 - 203.50
- Avg price
- 200.51
- Volume
- 1.19M
- Turnover
- 237.65M
- Turnover ratei
- 0.64%
- Volume ratioi
- 0.69
- Amplitudei
- 3.63%
- 52-week rangei
- 47.45 - 224.31
Valuation
- P/Ei
- -33.76
- P/E (TTM)i
- -22.65
- P/Bi
- 16.52
- EPSi
- -5.95
- Book value / shi
- 12.16
- Net profit
- -1.28B
- Net assets
- 2.61B
Share structure
- Market cap
- 43.05B
- Float capi
- 37.08B
- Shares out
- 214.34M
- Float sharesi
- 184.61M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-02-13
10.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+23.53M net over the window
Short interest
- Shares short
- 9.67M
- % of floati
- 4.51%
- Days to coveri
- 7.24
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Revolution Medicines (RVMD)?
Revolution Medicines last traded at 200.87. The quote on this page refreshes every few seconds while US markets are open.
What is Revolution Medicines's market cap?
About 43.05B.
What is the P/E ratio of Revolution Medicines?
The trailing twelve-month P/E is -22.65. The Valuation tab shows it against the stock's own five-year range.
Does Revolution Medicines pay a dividend?
Revolution Medicines does not currently pay a regular dividend.
Is Revolution Medicines a buy according to analysts?
The consensus of 22 analysts is a Buy rating, with an average 12-month price target of 261.75, which implies 30.3% upside from the current price. This is not investment advice.
What is Revolution Medicines's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Revolution Medicines a B (Buy). Twelve-month momentum in the top 1% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 07:27:19 · For reference only, not investment advice and not tailored to your situation.